Ovid Therapeutics Inc. (OVID) Tops Q3 EPS by 1c

Ovid Therapeutics Inc. (NASDAQ: OVID) reported Q3 EPS of ($0.20), $0.01 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $170 thousand versus the consensus estimate of $105.5 thousand.

For earnings history and earnings-related data on Ovid Therapeutics Inc. (OVID) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Venu Holding enters $250 million at-the-market stock offering agreement
• MIND Technology (MIND) Misses Q1 EPS by 5c